All News

There are certain side effects from Elahere — a newly approved ovarian cancer drug — that patients taking the treatment should look out for, an expert said.

Nowadays, I think of myself more as a cancer survivor and advocate than patient. Here's what I learned along the way.

From the reveal of Christine McVie’s cause of death to cancer news from Hugh Jackman and a U.S. congressman, here’s what’s happening in the oncology space this week.

This analysis of the KEYNOTE-826 trial focused on health-related quality of life in patients with persistent, recurrent or metastatic cervical cancer.

The day I got diagnosed with cancer, I went from “person” to “patient” — and the title has followed me ever since.

Social media, including Facebook groups, can help connect patients with rare cancers like granulosa cell tumors to researchers, allowing them to learn more about disease management.

After being diagnosed with aggressive bone cancer, I had to accept that much of my life was going to change.

Immunotherapy treatment with Opdivo before surgery improved recurrence-free survival and overall survival at five years in patients with non-small cell lung cancer.

Interim findings from a clinical trial showed that adding Lynparza and Imfinzi to an Avastin and chemotherapy regimen tended to improve the time patients lived before their disease got worse.

When a green dye was used to detect early signs of breast cancer-related lymphedema, patients tended to have better outcomes with the condition, recent research showed.

HER3-DXd proved to be safe and efficacious in treating patients with HER3-expressing metastatic breast cancer, recent study results showed.

Patients and cancer survivors shared their experiences with cannabis/medical marijuana to help relieve symptoms.

I learned that self-advocacy is not about proving an oncology wrong or deciding that one drug is better than the other. It’s about speaking up for what you think is right.

A prostate cancer expert lends insight to the nationwide Pluvicto shortage, and what eligible patients can do.

The Food and Drug Administration will review Braftovi plus Mektovi for the treatment of patients with metastatic BRAF V600E-mutant non-small cell lung cancer.

While I wouldn’t say that my cancer-related hospital stays were fun, I did my best to maintain a positive attitude and make the best of them.

Cryocompression was found to be tolerable and effective in preventing chemotherapy-induced peripheral neuropathy in a small study.

Sometimes, hundreds of pages of cancer information still just doesn’t connect with the person who needs it.

Researchers determined that mortality rates did not differ in men with localized prostate cancer if they underwent active monitoring, prostatectomy or radiotherapy.

A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.

The FDA approved the combination for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for treatment with cisplatin-based chemotherapy.

As caregivers become more integrated into the health care delivery process for patients with cancer, their own needs should still be focused on pertaining to mental and physical health.

I’m happy to be alive and thankful for all that I have, but cancer and the COVID-19 pandemic has taken so much from me, physically, emotionally and financially.

Patients with cancer may decide to share their diagnosis with their employer but approaching it in a way that is most comfortable to the patient may make it a more effective conversation.

There is no guidebook to life with cancer, but here a few important lessons I learned along the way.

While waiting for my daughter to get a prophylactic cancer surgery, I sketched a cartoon that I hope will get people talking about hereditary cancer risks.

People who have never experienced cancer may think that life continues as normal after treatment is done, but that’s far from reality.

Watch Dr. Rupesh Kotecha, from Miami Cancer Institute, Baptist Health South Florida, discuss the treatment of brain metastases during the CURE Educated Patient® Breast Cancer Summit at MBCC.

Patients with HR+/HER2- early breast cancer treated with the CDK4/6 inhibitor plus endocrine therapy in the phase 3 NATALEE trial had a reduced risk for the cancer to recur.

Two-year follow-up data showed that Rybrevant was promising in a difficult-to-treat subtype of non-small cell lung cancer.